Islamabad, August 5, 2025: The Drug Regulatory Authority of Pakistan (DRAP) has declared 11 batches of Famila 28F tablets, manufactured by Zafa Pharmaceuticals, as substandard following laboratory testing.
According to an official notification issued by DRAP’s Quality Control Directorate, the affected batches failed to meet the required quality standards during testing conducted by the Central Drugs Laboratory, Karachi.
In light of the laboratory findings, immediate instructions have been issued to withdraw the identified batches from the market to prevent any potential health risks to the public.
The batches declared substandard include K-217, K-177, K-207, K-203, K-184, K-190, K-191, K-182, K-199, K-205, and K-204.
DRAP has directed all relevant institutions, hospitals, and pharmacies to identify and remove these specific batches from circulation without delay, emphasizing the need to ensure public safety and minimize any associated health hazards.
